BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

1.7k

Active:134

Completed:1204

Trial Phases

6 Phases

Early Phase 1:1

Phase 1:574

Phase 2:352

+3 more phases

Drug Approvals

SFDA:10

CIMA_AEMPS:1

Drug Approvals

REVIA COMPRIMIDOS RECUBIERTOS

Approval Date: Jul 14, 2025

CIMA_AEMPS

Clinical Trials

Distribution across different clinical trial phases (1339 trials with phase data)• Click on a phase to view related trials

Phase 1

574 (42.9%)

Phase 2

352 (26.3%)

Phase 3

320 (23.9%)

Phase 4

53 (4.0%)

Not Applicable

36 (2.7%)

phase_1_2

2 (0.1%)

Early Phase 1

1 (0.1%)

phase_2_3

1 (0.1%)

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis

Not Applicable

Not yet recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: BMS-986454
Other: Placebo

First Posted Date: 2025-09-15

Last Posted Date: 2025-09-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 46

Registration Number: NCT07171983

Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Completed

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions: Drug: Mavacamten

First Posted Date: 2025-09-11

Last Posted Date: 2025-09-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 163

Registration Number: NCT07168655

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

Not Applicable

Not yet recruiting

Conditions: Solid Tumours

Interventions: Drug: BMS-986517

First Posted Date: 2025-09-08

Last Posted Date: 2025-09-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 315

Registration Number: NCT07160725

Locations: 🇺🇸
Local Institution - 0002, Los Angeles, California, United States
🇺🇸
Local Institution - 0021, Orange, California, United States
🇺🇸
Local Institution - 0008, Pittsburgh, Pennsylvania, United States

and more 13 locations

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Nivolumab + platinum-based chemotherapy

First Posted Date: 2025-08-26

Last Posted Date: 2025-08-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 80

Registration Number: NCT07141563

Locations: 🇦🇷
Grupo Argentino Oncología Torácica (GAOT) - Asociación Argentina Oncología Clínica (AAOC), Buenos Aires, Argentina

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Not Applicable

Not yet recruiting

Conditions: Mania
Bipolar Disorder

Interventions: Drug: Xanomeline/Trospium Chloride
Drug: Lithium
Drug: Valproate
Drug: Lamotrigine
Drug: Placebo

First Posted Date: 2025-08-26

Last Posted Date: 2025-09-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 424

Registration Number: NCT07140913

Locations: 🇺🇸
Local Institution - 0029, Bentonville, Arkansas, United States
🇺🇸
Local Institution - 0018, Little Rock, Arkansas, United States
🇺🇸
Local Institution - 0049, Chino, California, United States

and more 38 locations

News

Biocartis Receives FDA Approval for First Fully Automated Companion Diagnostic Test for Colorectal Cancer

15 hours ago

Biocartis has received FDA Premarket Approval for the Idylla™ CDx MSI Test, marking the first fully automated, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients.

BioNTech-Bristol Myers Bispecific Antibody Achieves 76.3% Response Rate in Small Cell Lung Cancer Phase II Trial

7 days ago

BioNTech and Bristol Myers Squibb's investigational bispecific antibody pumitamig (BNT327) demonstrated a 76.3% confirmed objective response rate in a Phase II trial for extensive-stage small cell lung cancer.

BioNTech and Bristol Myers Squibb Report Promising Phase 2 Results for Pumitamig in Extensive-Stage Small Cell Lung Cancer

8 days ago

BioNTech and Bristol Myers Squibb presented interim Phase 2 data showing pumitamig plus chemotherapy achieved a 76.3% confirmed objective response rate and 100% disease control rate in extensive-stage small cell lung cancer patients.

CHARM Therapeutics Appoints Dr. Erkut Bahceci as CMO to Lead Next-Generation Menin Inhibitor Development

8 days ago

CHARM Therapeutics has appointed Dr. Erkut Bahceci as Chief Medical Officer following an $80 million Series B financing to advance its next-generation menin inhibitor for acute myeloid leukemia.

Zydus and Synthon Partner to Launch Generic Multiple Sclerosis Drug in $637 Million US Market

12 days ago

Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with Netherlands-based Synthon BV to commercialize generic Ozanimod capsules for multiple sclerosis treatment in the US market.

Mavacamten Fails to Show Significant Benefit in Non-Obstructive Hypertrophic Cardiomyopathy Trial

17 days ago

The phase III ODYSSEY-HCM trial involving 580 patients showed mavacamten did not significantly improve symptoms or exercise capacity compared to placebo in non-obstructive hypertrophic cardiomyopathy patients at 48 weeks.

I-Mab Strengthens Leadership Team with Three New Board Appointments and R&D Committee Formation

22 days ago

I-Mab appointed three seasoned biotech executives to key leadership positions, including Dr. Robert Lenz and Ms. Xin Liu to the Board of Directors and Dr. Ken Takeshita to the Scientific Advisory Board.